Mylan Acquires Rights to Novel LAMA Respiratory Compound from Pfizer

Mylan (Nasdaq: MYL ) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready